570 completed, 162 terminated, 87 recruiting, 70 active not recruiting. 1019 Phase 2, 205 Phase 1, 25 Phase 3.
Follow Myeloproliferative Disorders: new trials by email Literature Review of Myeloproliferative Disorders trials Research Report on Myeloproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rusfertide in Adults With Polycythemia Vera in China Rusfertide - Polycythemia Vera | Phase 2 | Not yet recruiting | Takeda | 24 | 2027-03-01 | 2026-08-28 |
| Asciminib Frontline Risk Adapted Dasatinib 80mg QD (5 days per week), Standarc of Care - Chronic Myeloid Leukemia (CML) | Phase 2 | Not yet recruiting | Prof. Dr. med. Andreas Hochhaus | 200 | 2027-01-01 | 2026-09-04 |
| Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms Oral THU-decitabine - Myelofibrosis, MPN - Accelerated or Blast Phase | Phase 2 | Not yet recruiting | John Mascarenhas | 20 | 2027-01-01 | 2026-10-14 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Maintenance Therapy, No intervention - Myeloid Disorders, Myelodysplastic Syndromes | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 450 | 2026-12-01 | 2026-10-13 |
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms pacritinib - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 160 | 2026-11-04 | 2026-10-30 |
| Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera Epetraborole, Placebo - Polycythemia Vera (SNOMED CT: 109992005) | Phase 2 | Not yet recruiting | AN2 Therapeutics, Inc | 75 | 2026-11-01 | 2026-10-23 |
| Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis bomedemstat - Myelofibrosis | Phase 2 | Not yet recruiting | United Lincolnshire Hospitals NHS Trust | 40 | 2026-11-01 | 2026-02-20 |
| Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis Flonoltinib Maleate orally - Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera | Phase 2 | Not yet recruiting | Chengdu Zenitar Biomedical Technology Co., Ltd | 105 | 2026-11-01 | 2026-10-16 |
| Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI), Fludarabine, Cyclophosphamide - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 2 | Not yet recruiting | Stanford University | 30 | 2026-11-01 | 2026-09-30 |
| A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera AG-236, Placebo - Polycythemia Vera | Phase 2 / Phase 3 | Not yet recruiting | Agios Pharmaceuticals, Inc. | 245 | 2026-11-01 | 2026-10-13 |
| A Study of Ropeg-Interferon in People With Polycythemia Vera Ropeginterferon - Polycythemia Vera (PV), JAK2 Mutation | Phase 2 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 55 | 2026-10-30 | 2026-10-21 |
| Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 2 | Recruiting | John Mascarenhas | 26 | 2026-10-23 | 2026-10-27 |
| A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025). Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 380 | 2026-10-21 | 2026-10-21 |
| An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation gecacitinib Hydrochloride Tablets - Myeloid Neoplasms With Myelofibrosis | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 10 | 2026-10-15 | 2026-10-28 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2026-09-29 | 2026-05-06 |
| Pacritinib With Aza for Upfront Myelodysplastic Syndrome Pacritinib, Azacitidine, Bone Marrow Biopsy and Aspirate - Myelodysplastic Syndromes, MDS | Phase 1 / Phase 2 | Withdrawn | Thomas Jefferson University | 2026-09-01 | 2026-08-17 | |
| Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) Levofloxacin, Usual Care - Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) | Phase 2 | Not yet recruiting | University of Manitoba | 75 | 2026-09-01 | 2026-06-29 |
| A Study of Rusfertide in Japanese Adults With Polycythemia Vera Rusfertide - Polycythemia Vera | Phase 2 | Recruiting | Takeda | 9 | 2026-07-14 | 2026-10-02 |
Showing 20 of 1019. Sign in to see all of them.
Leukemia, Myeloid, Acute (407) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (404) · Myelodysplastic Syndromes (344) · Leukemia (313) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (303) · Primary Myelofibrosis (279) · Leukemia, Myeloid, Chronic-Phase (210) · Lymphoma, Non-Hodgkin (187) · Leukemia, Lymphocytic, Chronic, B-Cell (178) · Hodgkin Disease (170) · Blast Crisis (159) · Leukemia, Myeloid, Accelerated Phase (155) · Multiple Myeloma (155) · Congenital Abnormalities (143)
Hemic and Lymphatic Diseases (1018) · Bone Marrow Diseases (1006) · Hematologic Diseases (987) · Neoplasms (848) · Neoplasms by Histologic Type (781) · Leukemia, Myeloid (739) · Pathological Conditions, Signs and Symptoms (672) · Pathologic Processes (668) · Disease Attributes (664) · Chronic Disease (661) · Leukemia (463) · Immune System Diseases (384) · Immunoproliferative Disorders (364) · Lymphatic Diseases (360)
Cyclophosphamide (162) · fludarabine phosphate (141) · Busulfan (118) · Peripheral Blood Stem Cell Transplantation (106) · Mycophenolic Acid (100) · Tacrolimus (98) · Whole-Body Irradiation (95) · Imatinib Mesylate (88) · fludarabine (82) · Cyclosporine (81) · Cytarabine (81) · ruxolitinib (71) · Antilymphocyte Serum (70) · Methotrexate (69) · Filgrastim (64)
M.D. Anderson Cancer Center (96) · Fred Hutchinson Cancer Center (80) · National Cancer Institute (NCI) (56) · Novartis Pharmaceuticals (31) · Memorial Sloan Kettering Cancer Center (30) · Masonic Cancer Center, University of Minnesota (24) · Bristol-Myers Squibb (18) · City of Hope Medical Center (18) · Incyte Corporation (18) · National Heart, Lung, and Blood Institute (NHLBI) (18) · Case Comprehensive Cancer Center (15) · Roswell Park Cancer Institute (14) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (14) · H. Lee Moffitt Cancer Center and Research Institute (13) · John Mascarenhas (10)
United States (752) · Italy (112) · France (92) · Germany (88) · Canada (75) · United Kingdom (68) · Spain (59) · Australia (49) · South Korea (44) · Belgium (42) · Netherlands (35) · China (34) · Poland (34) · Israel (31) · Japan (28)
Jorge Cortes, MD (12) · Brenda Sandmaier (11) · John Mascarenhas, MD (11) · Michele Baccarani, MD (6) · Ronald Hoffman, MD (6) · Alessandro Rambaldi, MD (5) · Ayalew Tefferi, MD (5) · B. Douglas Smith, MD (5) · Jorge E Cortes, MD (5) · Judith Karp (5) · Albert Assad, MD (4)
PMID 32499241, PMID 23524640, PMID 28835440, PMID 30885996, PMID 23065508, PMID 23620574, PMID 25361995, PMID 35235189, PMID 35982483, PMID 41758981, PMID 17715389, PMID 18997171, PMID 21403127, PMID 22133778, PMID 22430088, PMID 24383844, PMID 25527568, PMID 31217161, PMID 31527168, PMID 35007144, PMID 36054756, PMID 40313042, PMID 10204198, PMID 11331327, PMID 11468154, PMID 11585760, PMID 11756187, PMID 12750167, PMID 15107815, PMID 15339678, PMID 15514371, PMID 15817673, PMID 16115130, PMID 16275934, PMID 16651647, PMID 16670265, PMID 16709929, PMID 16775235, PMID 16990776, PMID 17146105, PMID 17162214, PMID 17317857, PMID 17579184, PMID 17910637, PMID 18048643, PMID 18172005, PMID 18203012, PMID 18245545, PMID 18327587, PMID 18451242
P30CA015704 (32), P30CA006973 (16), P01CA018029 (14), P30CA043703 (11), P01CA108671 (10), 2017 (9), P30CA033572 (9), U01CA070095 (9), 2023 (8), P30CA016672 (8), U10CA031946 (8), U10CA032102 (8), 2018 (7), P01CA078902 (7), 2015 (6)